{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T10:36:26Z","timestamp":1793097386933,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.dmd.2026.100395","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:51:38Z","timestamp":1787755898000},"page":"100395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibition of cytochrome P450 2B6 activity by kava extracts"],"prefix":"10.1016","volume":"54","author":[{"given":"Pan-Fen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharathi","family":"Avula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Katragunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7047-5373","authenticated-orcid":false,"given":"Amar G.","family":"Chittiboyina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan D.","family":"Kharasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.dmd.2026.100395_bib1","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/nu12103044","article-title":"Kava as a clinical nutrient: promises and challenges","volume":"12","author":"Bian","year":"2020","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.dmd.2026.100395_bib2","article-title":"Kava extract for treating anxiety","volume":"2003","author":"Pittler","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.dmd.2026.100395_bib3","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/ptr.4916","article-title":"Kava for the treatment of generalized anxiety disorder: RCT: analysis of adverse reactions, liver function, addiction, and sexual effects","volume":"27","author":"Sarris","year":"2013","journal-title":"Phytother Res"},{"issue":"4","key":"10.1016\/j.dmd.2026.100395_bib4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/hup.581","article-title":"Enhanced cognitive performance and cheerful mood by standardized extracts of Piper methysticum (Kava-kava)","volume":"19","author":"Thompson","year":"2004","journal-title":"Hum Psychopharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100395_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/00048674.2010.522554","article-title":"Kava: a comprehensive review of efficacy, safety, and psychopharmacology","volume":"45","author":"Sarris","year":"2011","journal-title":"Aust N Z J Psychiatry"},{"issue":"2","key":"10.1016\/j.dmd.2026.100395_bib6","first-page":"335","article-title":"Kava as an anticraving agent: preliminary data","volume":"8","author":"Steiner","year":"2001","journal-title":"Pac Health Dialog"},{"key":"10.1016\/j.dmd.2026.100395_bib7","first-page":"420","article-title":"The correlation between cancer incidence and kava consumption","volume":"59","author":"Steiner","year":"2000","journal-title":"Hawaii Med J"},{"issue":"10","key":"10.1016\/j.dmd.2026.100395_bib8","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1093\/carcin\/bgu149","article-title":"Dihydromethysticin from kava blocks tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis and differentially reduces DNA damage in A\/J mice","volume":"35","author":"Narayanapillai","year":"2014","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.dmd.2026.100395_bib9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/19390211.2024.2327544","article-title":"Clinically relevant herb-drug interactions: a 30-year historical assessment","volume":"22","author":"Gurley","year":"2025","journal-title":"J Diet Suppl"},{"issue":"13","key":"10.1016\/j.dmd.2026.100395_bib10","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0024-3205(02)01913-6","article-title":"Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity","volume":"71","author":"Zou","year":"2002","journal-title":"Life Sci"},{"issue":"11","key":"10.1016\/j.dmd.2026.100395_bib11","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1124\/dmd.30.11.1153","article-title":"Inhibition of human cytochrome P450 activities by kava extract and kavalactones","volume":"30","author":"Mathews","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100395_bib12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1078\/0944711041495263","article-title":"Effects of kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes","volume":"11","author":"Zou","year":"2004","journal-title":"Phytomedicine"},{"issue":"10","key":"10.1016\/j.dmd.2026.100395_bib13","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1124\/dmd.105.004317","article-title":"Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro","volume":"33","author":"Mathews","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100395_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.109883","article-title":"In vitro inhibition of carboxylesterase 1 by Kava (Piper methysticum) kavalactones","volume":"357","author":"Melchert","year":"2022","journal-title":"Chem Biol Interact"},{"issue":"5","key":"10.1016\/j.dmd.2026.100395_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197940","article-title":"A stable isotope dilution tandem mass spectrometry method of major kavalactones and its applications","volume":"13","author":"Wang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.dmd.2026.100395_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115514","article-title":"Clinical pharmacokinetics of kavalactones after oral dosing of standardized kava extract in healthy volunteers","volume":"297","author":"Kanumuri","year":"2022","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.dmd.2026.100395_bib17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clpt.2005.01.009","article-title":"In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4\/5 phenotypes","volume":"77","author":"Gurley","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100395_bib18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/dmd.106.012708","article-title":"Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans","volume":"35","author":"Gurley","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100395_bib19","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/mnfr.200600300","article-title":"Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John\u2019s wort, and Echinacea","volume":"52","author":"Gurley","year":"2008","journal-title":"Mol Nutr Food Res. Nutr Food Res"},{"issue":"1","key":"10.1016\/j.dmd.2026.100395_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.clpt.6100222","article-title":"Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo","volume":"83","author":"Gurley","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100395_bib21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1124\/dmd.123.001578","article-title":"Natural products inhibition of cytochrome P450 2B6 activity and methadone metabolism","volume":"52","author":"Wang","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100395_bib22","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1124\/dmd.115.064352","article-title":"Differences in methadone metabolism by CYP2B6 variants","volume":"43","author":"Gadel","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100395_bib23","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/ALN.0000000000002371","article-title":"Stereoselective ketamine metabolism by genetic variants of cytochrome P450 CYP2B6 and cytochrome P450 oxidoreductase","volume":"129","author":"Wang","year":"2018","journal-title":"Anesthesiology"},{"issue":"5","key":"10.1016\/j.dmd.2026.100395_bib24","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/mam\/ozae095","article-title":"Utilization of advanced microscopy techniques and energy-dispersive x-ray spectroscopy to characterize three Piper species related to kava","volume":"30","author":"Adams","year":"2024","journal-title":"Microsc Microanal"},{"issue":"11-12","key":"10.1016\/j.dmd.2026.100395_bib25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/BF02497298","article-title":"Analytical techniques for the determination of lactones inPiper methysticum forst","volume":"50","author":"Ganzera","year":"1999","journal-title":"Chromatographia"},{"key":"10.1016\/j.dmd.2026.100395_bib26","first-page":"97","article-title":"Determination of CYP2B6 component of 7-ethoxy-4-trifluoromethylcoumarin O-deethylation activity in human liver microsomes","volume":"320","author":"Chang","year":"2006","journal-title":"Methods Mol Biol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100395_bib27","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1021\/acs.molpharmaceut.8b01214","article-title":"Halogen substitution influences ketamine metabolism by cytochrome P450 2B6: in vitro and computational approaches","volume":"16","author":"Wang","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.dmd.2026.100395_bib28","article-title":"Method for determination of formaldehyde","author":"Nakajima","year":"1984","journal-title":"U.S. Patent"},{"key":"10.1016\/j.dmd.2026.100395_bib29","series-title":"Method 8315A (SW-846): determination of carbonyl compounds by high performance liquid chromatography (HPLC), Revision 1","year":"1996"},{"key":"10.1016\/j.dmd.2026.100395_bib30","doi-asserted-by":"crossref","first-page":"W441","DOI":"10.1093\/nar\/gkp253","article-title":"IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding","volume":"37","author":"Cer","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.dmd.2026.100395_bib31","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1124\/jpet.111.183111","article-title":"Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome P450-reductase complex","volume":"338","author":"Zhang","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.dmd.2026.100395_bib32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/cpt.2166","article-title":"PharmVar GeneFocus: CYP2B6","volume":"110","author":"Desta","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100395_bib33","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1124\/dmd.108.023655","article-title":"Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs","volume":"37","author":"Talakad","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100395_bib34","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1021\/tx100412m","article-title":"Constituents in kava extracts potentially involved in hepatotoxicity: a review","volume":"24","author":"Olsen","year":"2011","journal-title":"Chem Res Toxicol"},{"issue":"14","key":"10.1016\/j.dmd.2026.100395_bib35","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.3390\/jcm11144039","article-title":"An updated review on the psychoactive, toxic and anticancer properties of kava","volume":"11","author":"Soares","year":"2022","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.dmd.2026.100395_bib36","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1111\/bcp.15393","article-title":"Methadone pharmacogenetics in vitro and in vivo: metabolism by CYP2B6 polymorphic variants and genetic variability in pediatric disposition","volume":"88","author":"Wang","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.dmd.2026.100395_bib37","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/dmd.119.086348","article-title":"Efavirenz metabolism: influence of polymorphic CYP2B6 variants and stereochemistry","volume":"47","author":"Wang","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2026.100395_bib38","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/dmd.119.090407","article-title":"Stereoselective bupropion hydroxylation by cytochrome P450 CYP2B6 and cytochrome P450 oxidoreductase genetic variants","volume":"48","author":"Wang","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2026.100395_bib39","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1124\/dmd.111.040352","article-title":"Functional characterization of CYP2B6 allelic variants in demethylation of antimalarial artemether","volume":"39","author":"Honda","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100395_bib40","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/FPC.0b013e32833bba0e","article-title":"Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22)","volume":"20","author":"Watanabe","year":"2010","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"10.1016\/j.dmd.2026.100395_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.468","article-title":"Nicotine oxidation by genetic variants of CYP2B6 and in human brain microsomes","volume":"7","author":"Bloom","year":"2019","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"10.1016\/j.dmd.2026.100395_bib42","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1124\/dmd.111.039347","article-title":"Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo","volume":"40","author":"Raccor","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100395_bib43","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1124\/dmd.115.063628","article-title":"Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome P450s and their commonly occurring polymorphisms","volume":"43","author":"Calinski","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100395_bib44","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1124\/dmd.111.042416","article-title":"Effects of the CYP2B6\u22176 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo","volume":"40","author":"Xu","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100395_bib45","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1124\/jpet.122.001277","article-title":"Influence of CYP2B6 pharmacogenetics on stereoselective inhibition and induction of bupropion metabolism by efavirenz in healthy volunteers","volume":"382","author":"Gufford","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.dmd.2026.100395_bib46","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/1389200003339270","article-title":"Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation","volume":"1","author":"Murray","year":"2000","journal-title":"Curr Drug Metab"},{"issue":"9","key":"10.1016\/j.dmd.2026.100395_bib47","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/ic400010d","article-title":"Carbene generation by cytochromes and electronic structure of heme-iron-porphyrin-carbene complex: a quantum chemical study","volume":"52","author":"Taxak","year":"2013","journal-title":"Inorg Chem"},{"issue":"12","key":"10.1016\/j.dmd.2026.100395_bib48","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1177\/0091270006293753","article-title":"Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6","volume":"46","author":"Walsky","year":"2006","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100395_bib49","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1007\/s13197-013-1047-2","article-title":"Kavalactone content and chemotype of kava beverages prepared from roots and rhizomes of Isa and Mahakea varieties and extraction efficiency of kavalactones using different solvents","volume":"52","author":"Wang","year":"2015","journal-title":"J Food Sci Technol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100395_bib50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/beverages10010004","article-title":"The kavalactone content and profile of Fiji kava sold on the local market","volume":"10","author":"Pasinszki","year":"2024","journal-title":"Beverages"},{"issue":"5","key":"10.1016\/j.dmd.2026.100395_bib51","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3390\/agriculture15050478","article-title":"Kavalactone content and profile of kava cultivated on Taveuni, Qamea, and Rabi Islands of Fiji","volume":"15","author":"Devi","year":"2025","journal-title":"Agriculture"},{"issue":"5","key":"10.1016\/j.dmd.2026.100395_bib52","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/pca.3019","article-title":"Simultaneous quantitation of kavalactones in kava dry extracts: comparison of multi-standards and single standard validation approaches","volume":"32","author":"Ferreira","year":"2021","journal-title":"Phytochem Anal"},{"issue":"14","key":"10.1016\/j.dmd.2026.100395_bib53","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1055\/a-1708-1994","article-title":"Characterization of different forms of kava (Piper methysticum) products by UPLC-MS\/MS","volume":"88","author":"Mamallapalli","year":"2022","journal-title":"Planta Med"},{"key":"10.1016\/j.dmd.2026.100395_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115080","article-title":"The impact of traditional kava (Piper methysticum) use on cognition: implications for driver fitness","volume":"291","author":"Aporosa","year":"2022","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.dmd.2026.100395_bib55","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.fitote.2014.11.012","article-title":"Contemporary Pacific and Western perspectives on 'awa (Piper methysticum) toxicology","volume":"100","author":"Showman","year":"2015","journal-title":"Fitoterapia"},{"issue":"4","key":"10.1016\/j.dmd.2026.100395_bib56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/scipharm86040043","article-title":"Pharmacokinetic enhancers (boosters)-escort for drugs against degrading enzymes and beyond","volume":"86","author":"Krau\u00df","year":"2018","journal-title":"Sci Pharm"},{"issue":"7","key":"10.1016\/j.dmd.2026.100395_bib57","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1124\/dmd.117.079962","article-title":"Recommended approaches for pharmacokinetic natural product-drug interaction research: a NaPDI center commentary","volume":"46","author":"Paine","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2026.100395_bib58","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1124\/dmd.120.000182","article-title":"Natural products: experimental approaches to elucidate disposition mechanisms and predict pharmacokinetic drug interactions","volume":"48","author":"Paine","year":"2020","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T10:20:18Z","timestamp":1793096418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0090955626006641"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100395","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of cytochrome P450 2B6 activity by kava extracts","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100395","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100395"}}